treatment strategies to maximise patient benefit in metastatic colorectal cancer

Associate Professor Winston Liauw

Cancer Care Centre St George Hospital

@wsliauw

TREATMENT STRATEGIES TO MAXIMISE PATIENT BENEFIT IN

METASTATIC COLORECTAL CANCER

CASE DISCUSSION• 52 male with past history stage 3 (T4aN1M0) colon cancer at age 49. Rx with adjuvant

FOLFOX. Has residual grade 1 neuropathy. Now presents with CEA 36. CT scan C/A/P shows liver metastases & PET scan shows no other disease.

• What do you want to do?

• It is decided to proceed directly to surgery at the preference of the patient and the surgeon.

• Intraoperative ultrasound discloses no new lesions but there is low volume peritoneal disease

• The surgeon calls you from operating theatre. What do you want to do?

CASE DISCUSSION

CASE DISCUSSION• The patient now comes to your rooms post surgery. The pathology disclosed completely

resected liver disease and the surgeon removed all of the peritoneal disease.

• What do you want to do?

CASE DISCUSSION• 1 year post liver resection CEA is normal but CT scan detects a 2 cm pulmonary nodule.

• What do you want to do?

EJSO 2013; 39:981-987.

World J Surg 2012; 36(2): 386.

Associate Professor Winston Liauw

Cancer Care Centre St George Hospital

TREATMENT STRATEGIES TO MAXIMISE PATIENT BENEFIT IN

METASTATIC COLORECTAL CANCER

OBJECTIVES

THERE WAS A LIMITED AMOUNT OF TIME SO RATHER THAN UNDERTAKE AN EXHAUSTIVE DISCUSSION OF THE TRIALS I’VE DECIDED TO FOCUS ON STRATGEIC

THINKING IN RELATION TO METASTATIC COLORECTAL CANCER MANAGEMENT

THE ART OF WAR AGAINST METASTATIC COLORECTAL CANCER

SUN TZU, The Art of War

“STRATEGY WITHOUT TACTICS IS THE SLOWEST ROUTE TO VICTORY. TACTICS

WITHOUT STRATEGY IS THE NOISE BEFORE DEFEAT”

“IF IGNORANT BOTH OF YOUR ENEMY AND YOURSELF, YOU ARE CERTAIN TO BE IN PERIL”

SUN TZU, The Art of War

UNDERSTAND

The disease you are treating

Your own approach to treatment

The preferences and understanding of the patient

UNDERSTAND THE DISEASE• BIOLOGICAL CONSIDERATIONS

• STAGE & PATTERN OF SPREAD

• TUMOUR IMMUNOLOGY

• GENOTYPE & PHENOTYPE

• THE AIM IS TO BE ABLE TO PROGNOSTICATE

• WHERE WILL RELAPSE / PROGRESSION OCCUR

• WHAT IS THE NATURAL AND MODIFIABLE TEMPO OF THE DISEASE

• THE OTHER AIM IS TO DETERMINE THE BEST TOOLS FOR TREATMENT

• TAILORING THERAPY

UNDERSTAND THE DISEASE

METASTATIC COLORECTAL CANCER

CAN BE A CHRONIC DISEASE

AND CAN BE CURED

WHAT IS YOUR APPROACH TO TREATMENT?

• THERE IS NO DOUBT THAT DIFFERENT ONCOLOGISTS HAVE DIFFERENT APPROACHES TO TREATMENT – SOME ARE CONSIDERED ‘AGGRESSIVE’ AND OTHERS ‘CONSERVATIVE’

• ANOTHER PERSPECTIVE COULD BE ‘CREATIVE’ VERSUS ‘UNCREATIVE’

• HOW DO YOU USE THE EVIDENCE?

• DO YOU KNOW THE OLDER LITERATURE & ALTERNATIVE AGENTS

• QUANTITY OF LIFE VERSUS QUALITY OF LIFE

• THE MEDIAN ISN’T THE MESSAGE

• IS THERE A LONG TAIL?

WHAT IS YOUR APPROACH TO TREATMENT?

UNDERSTAND THE PATIENT• TAKE INTO CONSIDERATION THE MEDICAL FACTORS

• AGE

• COMORBIDITIES

• ORGAN DYSFUNCTION

• TAKE INTO CONSIDERATION THE PATIENT PREFERENCES

• SOME WANT AGGRESSIVE THERAPY TO GAIN TIME

• SOME WANT TO FOCUS ON QUALITY OF LIFE

• SOME HAVE SPECIFIC GOALS

• UNDERLYING BELIEFS ARE IMPORTANT

SOME GUIDING PRINCIPLES

CONSIDER THE OVERALL APPROACH TO THE PROBLEM: WHAT IS THE TREATMENT INTENT?

UNDERTAKE (OR AIM TO UNDERTAKE) COMPLETE CYTOREDUCTION / RESECTION / ABLATION WHENEVER FEASIBLE

WITHIN EXPECTED PATIENT TOLERANCE USE THE MOST ACTIVE THERAPY FOR PHARMACOLOGICAL DEBULKING

SOME GUIDING PRINCIPLES

WHERE POSSIBLE TAILOR THE PHARMACOTHERAPY (PHARMACOGENETICS)

EXPLOIT THE HALLMARKS OF CANCER

USE MAINTENANCE THERAPY WHERE POSSIBLE

CONSIDER RE-CHALLENGE

CAVEATS TO THE GUIDING PRINCIPLES

TAKE A TOXICITY SPARING APPROACH

AVOID BURNING BRIDGES TOO EARLY

WHAT IS THE INTENT OF TREATMENT?• DETERMINING THE INTENT OF TREATMENT HELPS DETERMINE THE TREATMENT

CHOICE

• E.G. YOUNG PERSON WITH BILOBAR LIVER METASTASES POTENTIALLY TREATABLE WITH 2-STAGE LIVER RESECTION WITH INTENT TO CURE

• USE MOST INTENSE REGIMEN E.G. FOLFOXIRI + BEVACIZUMAB

• C.W. ELDERLY PERSON WITH SAME DISEASE AND THE INTENT IS PALLIATION

• USE LESS INTENSE CHEMOTHERAPY

UNDERTAKE RESECTION WHEN POSSIBLE

ALMOST REGARDLESS OF THE SITE OF METASTASIS SURGICAL THE 5 –YEAR SURVIVAL IS 25% IF R0 RESECTION IS ACHIEVED

J Clin Oncol. 2010; 28(1):63-8. J Gastrointest Surg. 2013;17(2):352-9

Cancer. 2010;116(9):2106-14. Ann Surg Oncol 2011; 18: 1560

WITHIN EXPECTED PATIENT TOLERANCE USE THE MOST ACTIVE THERAPY FOR PHARMACOLOGICAL

DEBULKING

LANCET. 2000 JUL 29;356(9227):373-8.

WHERE POSSIBLE TAILOR THE PHARMACOTHERAPY (PHARMACOGENETICS)

CLIN CANCER RES. 2011;17(17):5783-92.

EXPLOIT THE HALLMARKS OF CANCER

EXPLOIT THE HALLMARKS OF CANCER• By targeting more than one hallmark simultaneously one might achieve better results

• In particular there is the case that continuing treatment beyond progression may be advantageous for some of the hallmarks:

• Bevacizumab in colon cancer

• Trastuzumab in breast cancer

• Hormonal therapy

• In addition some combinations may reverse resistance e.g. cetuximab and irinotecan

USE MAINTENANCE THERAPY WHERE POSSIBLE

J CLIN ONCOL. 2007 NOV 20;25(33):5218-24.

USE MAINTENANCE THERAPY WHERE POSSIBLE• Current evidence is mixed and there aren’t clear rules.

• Guidelines:

• Oxaliplatin re-introduction feasible and generally safe

• Maintenance probably translates in to small survival increment

• Treatment break probably translates into small QOL increment

• Time off chemotherapy generally short

• Use the prognostic factors relevant from the original presentation to guide choices

• Use patient preferences

USE MAINTENANCE THERAPY WHERE POSSIBLE• If the cancer doesn’t progress, and the patient is well, the patient will live longer

• Currently the main strategy is maintenance chemotherapy +/- biological agent

• Future role for immunotherapy

CONSIDER RE-CHALLENGE• We assume that a cancer is resistant to a therapeutic agent after prior progression

• In practice given the long time frames re-challenge is possble

• Oxaliplatin both in post-adjuvant and protracted treatment setttings

CAVEAT: TAKE A TOXICITY SPARING APPROACH• One of the problems is cumulative toxicity, particularly with oxaliplatin

• There has been historical trend to use oxaliplatin in first-line rather than irinotecan but it may be better to do in reverse

• Paradoxically some of the combinations (FOLFIRI vs irinotecan) might have more favourable profile

CAVEAT: AVOID BURNING BRIDGES TOO EARLY

LANCET. 2007 JUL 14;370(9582):135-42.

SUMMARISING THE STRATEGY

USE ALL OF THE AVAILABLE TOOLS (TACTICS)

BUT TAILOR THEIR USE TO THE INTENT OF THE TREATMENT

WITH THE OVERALL STRATEGY OF PROVIDING THE LONGEST DURATION OF LIFE WITH THE BEST POSSIBLE QUALITY OF LIFE AND THE LEAST AMOUNT OF TOXICITY

“MANY CALCULATIONS LEAD TO VICTORY, AND FEW CALCULATIONS TO DEFEAT”

Sun Tzu, The Art of War